Protalix Plans US Resubmission For ERT For Fabry After Positive Phase III Trial Results

 
• By Jessica Merrill
submit button
Protalix hopes to resubmit its Fabry drug to FDA • Source: Alamy

More from Clinical Trials

More from R&D